Company Overview - ADC Therapeutics is a commercial stage company focused on antibody drug conjugates, particularly known for its CD19-directed product, ZYNLONTA [1] - ZYNLONTA is currently approved for use in the third line plus DLBCL setting, with plans to expand into earlier lines of DLBCL and indolent lymphomas [1] Clinical Studies - The LOTIS-5 study is a Phase III confirmatory trial of ZYNLONTA in combination with rituximab, with results expected in the second quarter of this year [2] - The LOTIS-7 study is investigating ZYNLONTA plus glofitamab in second line plus DLBCL, with results anticipated by the end of this year [2]

Financial Performance - ADC Therapeutics reported Q4 net product revenue of $22.3 million and full-year revenue of $73.6 million for 2025, driven by stable demand and higher selling prices [1] - The company achieved a significant reduction in net loss, totaling $142.6 million for the full year compared to $157.8 million in 2024, attributed to lower R&D expenses and organizational optimization [3] Cash Position - As of December 31, 2025, ADC Therapeutics had $261.3 million in cash and cash equivalents, with expectations for the cash runway to extend at least into 2028 [1] Clinical Pipeline - The company is approaching several value-creating catalysts, with topline data from the LOTIS-5 Phase 3 trial expected in Q2 2026 and full results anticipated by year-end [2] - Positive results from these trials could lead to a supplemental Biologics License Application (sBLA) and potential compendia inclusions in 2027 [2] - Investigator-initiated trials are also evaluating ZYNLONTA for other B-cell malignancies, with data expected between late 2026 and mid-2027 [2] Company Overview - ADC Therapeutics specializes in antibody drug conjugate technology, with its flagship product being ZYNLONTA, a CD19-directed ADC [4]

Core Insights - ADC Therapeutics is focusing on expanding ZYNLONTA while significantly reducing costs, with a strategy that includes multiple clinical and regulatory catalysts expected in 2026 and 2027 [4][5][15] Financial Performance - In Q4 2025, net product revenue was $22.3 million, an increase from $16.4 million in Q4 2024, while full-year net product revenue reached $73.6 million, compared to $69.3 million in 2024 [12][14] - The company reported a Q4 GAAP net loss of $6.4 million, improving from a net loss of $30.7 million in Q4 2024, and a full-year net loss of $142.6 million, down from $157.8 million in 2024 [14] - Total operating expenses were $41.0 million in Q4 and $202.9 million for the full year, with adjusted operating expenses down 15% and 6% year-over-year, respectively [13] Strategic Focus - The company has implemented a plan for optimized lifecycle management of ZYNLONTA, including the Phase III LOTIS-5 study and the bispecific combination study LOTIS-7 [3][5] - ADC Therapeutics has reduced its operating cost structure by approximately 50% as part of its restructuring efforts [3][5] Clinical Programs - Management emphasized the expansion into second-line-plus DLBCL as a primary growth opportunity, with LOTIS-5 top-line data expected in Q2 2026 [7][18] - In LOTIS-5, an overall response rate of 80% and a complete response rate of 50% were reported, supporting the potential for a regimen combining ZYNLONTA with rituximab [8] - LOTIS-7 has expanded target enrollment to approximately 100 patients, with a reported 90% best overall response rate and a 78% complete response rate [9] Balance Sheet and Future Outlook - The company ended 2025 with $261.3 million in cash and cash equivalents, up from $250.9 million at the end of 2024, supported by $100 million and $60 million PIPE financings [15] - Management believes it has laid the foundation for multiple anticipated value-creating catalysts ahead, with a strengthened cash runway supporting execution for potential growth beginning in 2027 [15]

Core Insights - ADC Therapeutics has set a peak revenue target for ZYNLONTA between $600 million and $1 billion as it advances clinical trials LOTIS-5 and LOTIS-7 [2] Management Strategy - CEO Ameet Mallik emphasized a strategic focus on ZYNLONTA, which includes optimized life cycle management and the advancement of clinical trials [2] - The company aims to reduce operating costs by concentrating its efforts on ZYNLONTA and related trials [2]

Financial Data and Key Metrics Changes - In Q4 2025, net product revenues were $22.3 million, up from $16.4 million in Q4 2024, indicating a strong performance [21] - For the full year 2025, net product revenues reached $73.6 million, compared to $69.3 million in 2024, showing stability in revenue generation [21] - Total operating expenses for Q4 2025 were $41 million, while for the full year, they were $202.9 million, reflecting a disciplined approach to cost management [21][22] - The net loss for Q4 2025 was $6.4 million, significantly reduced from a loss of $30.7 million in Q4 2024 [22][23] Business Line Data and Key Metrics Changes - The focus on ZYNLONTA has led to a refined go-to-market model, maintaining its position in the third-line plus DLBCL setting despite increased competition from bispecific therapies [5][6] - The company anticipates significant growth opportunities in the second-line plus DLBCL setting with LOTIS-5, expecting to share top-line data in Q2 2026 [8][10] Market Data and Key Metrics Changes - The treatment landscape for DLBCL is evolving, with a current 60/40 split between complex therapies and broadly accessible therapies, impacting market dynamics [15] - The company estimates that achieving a 10% market share in the second-line setting could translate to an additional $200 million to $300 million in revenue [20] Company Strategy and Development Direction - The strategic plan focuses on optimizing lifecycle management for ZYNLONTA, including advancing LOTIS-5 and initiating LOTIS-7 [5][6] - The company aims to establish ZYNLONTA as a backbone therapy in DLBCL, targeting peak annual revenues of $600 million to $1 billion with regulatory approvals and compendia listings [7][11] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in the company's path forward, highlighting a strengthened balance sheet and a cash runway expected to last into 2028 [10][24] - The anticipated data catalysts in 2026 are expected to drive significant long-term growth, particularly with the LOTIS-5 and LOTIS-7 trials [25][26] Other Important Information - The company has successfully reduced its operating cost structure by approximately 50%, enhancing its strategic flexibility [5][6] - The amendment to the royalty purchase agreement with HealthCare Royalty reflects the company's confidence in ZYNLONTA's long-term value [9][10] Q&A Session Summary Question: How are PFS events tracking for LOTIS-5? - Management is confident in the Q2 timing for the top-line readout and will share primary and secondary endpoints at that time [29][30] Question: Is the $200-$300 million opportunity for LOTIS-5 conservative? - Management believes the profile seen in the safety run-in supports a meaningful role in the second-line plus DLBCL market, with potential for higher peak sales depending on clinical outcomes [34][35] Question: What is the expected R&D spend moving forward? - R&D expenses are expected to decrease in 2026 and 2027, assuming the current number of trials remains stable [42][44] Question: How will capital allocation priorities be managed? - The company is focused on driving ZYNLONTA growth and has allocated capital for ongoing trials and pre-launch activities [48][50] Question: What is the current commercial run rate for ZYNLONTA? - The company has maintained its market share despite increased competition, with expectations for significant sales growth following LOTIS-5 approval [58][59]

Financial Data and Key Metrics Changes - ZYNLONTA net product revenues in Q4 2025 were $22.3 million, up from $16.4 million in Q4 2024, with full-year revenues at $73.6 million compared to $69.3 million in 2024 [21][22] - Total operating expenses were $41 million for Q4 2025 and $202.9 million for the full year, with adjusted operating expenses down 15% for Q4 and 6% for the full year compared to the previous year [21][22] - The net loss for Q4 2025 was $6.4 million, significantly reduced from a net loss of $30.7 million in Q4 2024, while the full-year net loss was $142.6 million compared to $157.8 million in 2024 [22][23] Business Line Data and Key Metrics Changes - The company focused on ZYNLONTA, optimizing lifecycle management and advancing clinical trials such as LOTIS-5 and LOTIS-7, which are expected to drive future growth [5][6] - The performance in Q4 was strong, driven by variability in customer ordering patterns and activation of new accounts, indicating a positive trend in sales [8] Market Data and Key Metrics Changes - The company anticipates a peak annual U.S. revenue opportunity for ZYNLONTA of $600 million to $1 billion, contingent on regulatory approval and compendia inclusion [7][11] - The treatment landscape for DLBCL is evolving, with a current 60/40 split between complex therapies and broadly accessible therapies, indicating a competitive market environment [15] Company Strategy and Development Direction - The strategic plan focuses on establishing ZYNLONTA as a backbone therapy in DLBCL, with significant patient benefits expected in indolent lymphomas [6][11] - The company aims to maintain a strong market position despite increased competition from bispecific therapies, leveraging its differentiated clinical profile [5][15] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in achieving key milestones in 2026, including top-line data for LOTIS-5 and further data for LOTIS-7, which are critical for future growth [25][26] - The company believes it has laid a solid foundation for long-term growth, with a strengthened balance sheet and a cash runway extending into 2028 [10][24] Other Important Information - The company has made significant progress in reducing operating costs by approximately 50% while enhancing its leadership and talent across the organization [5][6] - An amendment to the royalty purchase agreement with HealthCare Royalty has provided greater strategic flexibility for the company [10] Q&A Session Summary Question: How are PFS events tracking for LOTIS-5? - Management is confident in the Q2 timing for the top-line readout and will share primary and secondary endpoints at that time [29][30] Question: Is the $200-$300 million opportunity for LOTIS-5 conservative? - Management believes the profile seen in the safety run-in supports a meaningful role in the second-line DLBCL market, with potential for higher peak sales depending on clinical outcomes [34][35] Question: What is the expected R&D spend moving forward? - R&D expenses are expected to decrease in 2026 and 2027, assuming the current number of trials remains stable [42][44] Question: How should capital allocation priorities be viewed? - The company is focused on driving ZYNLONTA growth and has allocated capital for ongoing trials and pre-launch activities, with strategic flexibility provided by the amended royalty agreement [48][50] Question: What is the current commercial run rate for ZYNLONTA? - The company has maintained its market share despite increased competition, with expectations for significant sales growth following LOTIS-5 approval [58][59]

Financial Data and Key Metrics Changes - In Q4 2025, net product revenues were $22.3 million, up from $16.4 million in Q4 2024, indicating a significant increase [23] - For the full year 2025, net product revenues reached $73.6 million, compared to $69.3 million in 2024, showing stable performance [23] - Total operating expenses for Q4 2025 were $41 million, while for the full year, they were $202.9 million, reflecting a disciplined cost management approach [23] - The net loss for Q4 2025 was $6.4 million, a significant improvement from a net loss of $30.7 million in Q4 2024 [25] - The full year net loss was $142.6 million, down from $157.8 million in 2024, primarily due to reduced R&D expenses [25] Business Line Data and Key Metrics Changes - The company focused on ZYNLONTA, achieving a stable revenue stream in the third-line plus DLBCL setting, with a strong Q4 performance driven by new account activations [5][9] - The strategic reprioritization led to a reduction in operating costs by approximately 50%, enhancing the company's financial flexibility [5][8] Market Data and Key Metrics Changes - The company anticipates a peak annual revenue opportunity of $600 million to $1 billion for ZYNLONTA, contingent on regulatory approval and compendia inclusion [7][12] - The treatment landscape for DLBCL is evolving, with a current 60/40 split between complex therapies and broadly accessible therapies, indicating a competitive market environment [16] Company Strategy and Development Direction - The strategic plan focuses on optimizing lifecycle management for ZYNLONTA, including advancing LOTIS-5 and initiating LOTIS-7 [5][6] - The company aims to establish ZYNLONTA as a backbone therapy in second-line plus DLBCL, while also expanding into indolent lymphomas [6][12] - The management emphasized the importance of maintaining a strong cash position to support ongoing and future clinical trials [11][28] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in achieving significant long-term growth starting in 2027, driven by anticipated data catalysts and regulatory approvals [28] - The company remains optimistic about the potential for ZYNLONTA to reach a broader patient population through expanded indications [12][19] Other Important Information - The company ended 2025 with a cash balance of $261 million, providing a cash runway into 2028 [26] - An amendment to the royalty purchase agreement with HealthCare Royalty was made, enhancing strategic flexibility [11] Q&A Session Summary Question: How are PFS events tracking for LOTIS-5? - Management is confident in the Q2 timing for the top-line readout and will share primary and secondary endpoints at that time [30][31] Question: Is the $200-$300 million opportunity for LOTIS-5 conservative? - Management believes the profile seen in the safety run-in supports a meaningful role in second-line plus DLBCL, with potential for higher sales if the clinical profile is favorable [35][36] Question: What is the expected R&D spend going forward? - R&D expenses are expected to decrease in 2026 and 2027, assuming the current number of trials remains stable [43][45] Question: How should capital allocation priorities be viewed? - The company is focused on driving ZYNLONTA growth and has allocated capital for ongoing trials and pre-launch activities [48][51] Question: What is the current commercial run rate for ZYNLONTA? - Management is pleased with maintaining market share despite increased competition and anticipates significant sales growth with LOTIS-5 approval [60][61]

Summary of ADC Therapeutics FY Conference Call Company Overview - **Company**: ADC Therapeutics (NYSE:ADCT) - **Industry**: Biotechnology, specifically focusing on antibody-drug conjugates (ADCs) - **Key Product**: ZYNLONTA, a CD19-directed ADC approved for third-line plus DLBCL Core Points and Arguments 1. **Strategic Focus**: ADC Therapeutics aims to expand ZYNLONTA's use into earlier lines of therapy for DLBCL and indolent lymphomas, supported by multiple ongoing studies [2][3] 2. **Data Readouts**: 2026 is a critical year for the company with pivotal phase 3 data readouts expected soon, which could lead to expanded product approvals and market growth [2][3] 3. **Efficacy of ZYNLONTA**: The product demonstrates rapid, deep, and durable efficacy, with a 25% complete response (CR) rate in the third-line plus indication, and a mean duration of CR not reached even after 2 years [3][4] 4. **Safety Profile**: ZYNLONTA has a manageable safety profile with no cytokine release syndrome (CRS) or immune effector cell-associated neurotoxicity syndrome (ICANS), making it easier to administer compared to other therapies [4][5] 5. **Market Position**: In the third-line setting, complex therapies hold a 60% market share, while broadly accessible therapies, including ZYNLONTA, account for 40% [6][7] 6. **Combination Studies**: Ongoing studies (LOTIS-5 and LOTIS-7) are exploring combinations of ZYNLONTA with other therapies, which could enhance efficacy and market share [5][9] 7. **Revenue Potential**: Current sales are approximately $73 million, with potential growth to $200 million-$300 million by capturing a 5%-10% share in the second-line market [20][36] Additional Important Content 1. **LOTIS-5 Study**: This pivotal phase 3 study compares ZYNLONTA plus rituximab against R-GemOx, with a primary endpoint of progression-free survival (PFS) [13][14] 2. **LOTIS-7 Study**: Focuses on ZYNLONTA plus glofitamab, showing promising safety and efficacy data, with a 90% overall response rate and 78% CR rate in initial patients [27][29] 3. **Indolent Lymphoma Studies**: ADC Therapeutics is also exploring ZYNLONTA's efficacy in marginal zone lymphoma and follicular lymphoma, with promising early results [32][34] 4. **Market Dynamics**: The company recognizes the competitive landscape, particularly the growing share of bispecific therapies in the second-line setting, and aims to position ZYNLONTA effectively [9][10] 5. **Future Milestones**: Key upcoming milestones include data readouts for LOTIS-5 and LOTIS-7, with expectations for regulatory submissions and potential approvals in the near future [36][37] This summary encapsulates the critical insights from the ADC Therapeutics FY Conference Call, highlighting the company's strategic direction, product efficacy, market positioning, and future growth potential.

Core Viewpoint - ADC Therapeutics has amended its royalty purchase agreement with HealthCare Royalty, enhancing strategic flexibility and reducing financial obligations related to potential change of control events [2][3]. Financial Terms - The change of control payment has been reduced from $750 million to $150 million until the end of 2027, and to $200 million thereafter [2][6]. - HealthCare Royalty will continue to receive royalties on sales by any acquirer until the original royalty cap is reached [2]. - HealthCare Royalty has been granted warrants to purchase approximately 9.8 million common shares at an exercise price of $3.81 per share, exercisable until December 31, 2030, with a lock-up period until the end of 2027 [2][3]. Product Overview - ZYNLONTA is a CD19-directed antibody drug conjugate (ADC) designed to treat adult patients with relapsed or refractory large B-cell lymphoma [5][9]. - The FDA and EMA have approved ZYNLONTA for patients after two or more lines of systemic therapy, with the potential for peak revenue in the U.S. estimated between $600 million to $1 billion annually [3][7]. Company Background - ADC Therapeutics is a commercial-stage global leader in the field of antibody drug conjugates, focusing on innovative treatments through its portfolio, including ZYNLONTA [8][10].

Core Insights - ADC Therapeutics is focused on expanding the use of its approved product ZYNLONTA in earlier lines of DLBCL and indolent lymphomas, with significant accomplishments expected in 2025 [2] - The company aims to derisk its portfolio of trials for ZYNLONTA and strengthen its capital position through restructuring and equity raises [2] - Key data disclosures for multiple studies are anticipated in 2025, with expected growth starting in 2027 and continuing into 2028 and beyond [3] Company Overview - ADC Therapeutics operates in the ADC (Antibody-Drug Conjugate) space and has an approved product, ZYNLONTA, which is a CD19 directed ADC using a PBD-based warhead [3] - The company is preparing for final data disclosures in 2025, which are crucial for derisking its clinical trials [3] - The anticipated approval and compendia inclusion for multiple new uses of ZYNLONTA are expected to drive growth from 2027 onwards [3]